|
Vecuronium Bromide
API |
|
|
|
Haorui supplies high quality Vecuronium Bromide API produced by our
GMP facility that has been successfully inspected by the
FDA.
We offer
competitive prices and support our products with reliable technical and
regulatory services. Vecuronium Bromide API is available from R&D to
commercial quantities. Please contact us for more details. |
| |
|
The following
information is provided for general information purposes
ONLY. |
|
|
|
What is Vecuronium Bromide? |
|
Vecuronium Bromide is a muscle relaxant in
the category of non depolarising neuromuscular blocking
agents. Vecuronium bromide is indicated as an adjunct to
general anesthesia, to facilitate endotracheal intubation
and to provide skeletal muscle relaxation during surgery or
mechanical ventilation. |
|
|
|
Vecuronium bromide Chemical Name |
|
(+)-1-(3,17-Diacetoxy-2-piperidino-5-androstan-16-yl)-1-methylpiperidinium
bromide |
|
|
|
Vecuronium bromide CAS#:
50700-72-6 |
|
|
|
Vecuronium bromide Chemical Formula:
C34H57BrN2O4 |
|
|
|
Vecuronium bromide Molecular Weight:
637.74 |
|
|
|
Vecuronium bromide Drug Interaction |
|
-Bacitracin / High
IV or IP bacitracin doses
-muscle relaxation
Sodium colistimethate / High IV or IP sodium
colistimethate doses
-muscle relaxation
Tetracyclines / High IV or IP tetracycline doses
-muscle relaxation
Succinylcholine Vecuronium effect |
|
|
|
Vecuronium bromide Clinical Pharmacology |
|
Vecuronium operates by competing for the cholinergic
receptors at the motor end plate thereby exerting its muscle
relaxing properties which are used adjunctively to general
anesthesia. Under balanced anesthesia, the time to recovery
to 25% of control (clinical duration) is approximately 25 to
40 minutes after injection and recovery is usually 95%
complete approximately 45 to 65 minutes after injection of
intubating dose. The neuromuscular blocking action of
vecuronium is slightly enhanced in the presence of potent
inhalation anesthetics. If vecuronium is first administered
more than 5 minutes after the start of the inhalation of
enflurane, isoflurane, or halothane, or when steady state
has been achieved, the intubating dose of vecuronium may be
decreased by approximately 15%.
Vecuronium is normally given at 0.08-0.1mg/kg intravenously
and its maintenance dose is usually between 0.02-0.03mg/kg,
but as with all other neuromuscular blocking agents, the
doses need to be tailored for each individual patient. |
|
|
|
Disclaimer:
|
|
Information on
this page is provided for general information
purposes. You should not make a clinical treatment
decision based on information contained in this page
without consulting other references including the
package insert of the drug, textbooks and where
relevant, expert opinion. We cannot be held
responsible for any errors you make in administering
drugs mentioned on this page, nor for use of any
erroneous information contained on this page.
|
|
|
